Recombinetics Launches TARGET-TB with Researchers in the Republic of Ireland and Northern Ireland to Develop Genome Editing Solutions for Bovine Tuberculosis

Research aims to reduce the public health risk and financial costs associated with this disease Recombinetics announced today the launch of TARGET-TB, a tripartite collaborative research project with University College Dublin in the Republic of Ireland and Queen’s University Belfast in Northern Ireland to combat Mycobacterium bovis (M. bovis) infection, [...]

Recombinetics Launches TARGET-TB with Researchers in the Republic of Ireland and Northern Ireland to Develop Genome Editing Solutions for Bovine Tuberculosis2018-10-05T18:21:36-05:00

Recombinetics Announces New Board of Directors with Representatives from a Series A Strategic Investor: Gundersen Health System

Recombinetics today announced its new board of directors following this week’s completion of a $34 million Series A financing round. Gundersen Health System, a physician-led, not-for-profit healthcare system with locations in Wisconsin, Minnesota and Iowa, led the round as a strategic investor and now has three representatives on Recombinetics’ Board. [...]

Recombinetics Announces New Board of Directors with Representatives from a Series A Strategic Investor: Gundersen Health System2018-08-24T12:00:55-05:00
Go to Top